Can you take Iptacopan with Protopic?

Iptacopan has a moderate potential interaction with Hemodialysis.

No clinically significant differences in the exposure of iptacopan were observed between patients with estimated GFR in the range of 25 to less than 90 mL/min compared to those with normal estimated GFR. No data are available in patients on dialysis.

The tacrolimus topical in Protopic has a major potential interaction with Immunodeficiency.

The use of calcineurin inhibitors as pimecrolimus and tacrolimus topical should be avoided in immunocompromised adults and children, including patients on systemic immunosuppressive medications. Although causal relationship has not been established, there is a concern about a potential risk of infections, lymphomas and skin malignancies when using topical calcineurin inhibitors for a prolonged time.

Iptacopan has a major potential interaction with Infection.

Initiation of therapy with iptacopan is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type B. Complete or update vaccination against encapsulated bacteria at least 2 weeks before the first dose of iptacopan, according to current Advisory Committee on Immunization Practices (ACIP) recommendations for patients on complement inhibitors. Antibacterial drug prophylaxis is recommended for patients who require urgent iptacopan therapy but are not up to date with vaccines against encapsulated bacteria according to ACIP recommendations; such patients should receive these vaccines as soon as possible. Interruption of iptacopan should be considered in patients who are undergoing treatment for serious infections.

Iptacopan has a moderate potential interaction with Liver Disease.

The use of iptacopan is not recommended in patients with severe liver dysfunction (Child-Pugh C). No dose adjustment is needed for patients with mild or moderate liver dysfunction (Child-Pugh A or B).

Iptacopan has a moderate potential interaction with Peritoneal dialysis.

No clinically significant differences in the exposure of iptacopan were observed between patients with estimated GFR in the range of 25 to less than 90 mL/min compared to those with normal estimated GFR. No data are available in patients on dialysis.

The tacrolimus topical in Protopic has a moderate potential interaction with Renal Dysfunction.

Rare postmarketing cases of acute renal failure have been reported in patients treated with topical tacrolimus. Systemic absorption is most likely to occur in patients with epidermal barrier defects, and when topical tacrolimus is applied to large body surface areas. Caution should be exercised in patients with history of renal impairment or predisposed to renal impairment.

The tacrolimus topical in Protopic has a moderate potential interaction with Skin Cancer.

The use of calcineurin inhibitors such as pimecrolimus and tacrolimus topical should be avoided on malignant or premalignant skin conditions. Some of these conditions might present as dermatitis. Calcineurin inhibitors should also be avoided in any skin conditions where there is the potential for increased systemic absorption of the medication as when there is a skin barrier defect.